Company intelligence / Profile preview

Allterum Therapeutics

Houston, Texas, United Statesallterum.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Allterum is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia and other CD127-expressing cancers. The company is preparing to launch Phase I/II clinical trials. Pre-clinical studies have shown promise for the treatment of CD127-expressing cancers.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

4A10

1 more asset in the full pipeline.

Request access →

Partnerships

Baylor College of MedicineTexas Children's HospitalChildren's Oncology Group (COG)National Cancer Institute (NCI)Leukemia and Lymphoma SocietyUniversity of Texas MD Anderson Cancer CenterFUJIFILM Diosynth BiotechnologiesThe Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)

Beyond the preview

Go deeper on Allterum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allterum Therapeutics.

Explore the full profile